摘要
OBJECTIVE To improve the diagnosis and treatment level of critically ill infectious diseases, standardize the clinical application of nanopore sequencing and promote the sound development of the technology. METHODS Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society and Expert Committee of Precision Medicine for Clinical Treatment of Guangdong Pharmaceutical Association initiated and organized multidisciplinary experts to discuss and determine the consensus writing outline by using the nominal group method, forming a preliminary consensus draft; expert consultation was performed by using Delphi method, and then experts’ opinions were analyzed and revised to form consensus. RESULTS & CONCLUSIONS Consensuses of Experts on the Application of Nanopore Sequencing Technology in the Detection of Pathogenic Microorganisms covers targeted sequencing, metagenomic sequencing and whole genome sequencing, and is standardized in terms of sample collection and storage, detection process, bioinformatics analysis and report interpretation; the recommendations are provided for the key issues.
摘要
Hepatosteatosis is characterized by abnormal accumulation of triglycerides(TG),leading to prolonged and chronic inflammatory infiltration.To date,there is still a lack of effective and economical therapies for hepatosteatosis.Oridonin(ORI)is a major bioactive component extracted from the traditional Chinese medicinal herb Rabdosia rubescens.In this paper,we showed that ORI exerted significant protective ef-fects against hepatic steatosis,inflammation and fibrosis,which was dependent on LXRα signaling.It is reported that LXRα regulated lipid homeostasis between triglyceride(TG)and phosphatidylethanol-amine(PE)by promoting ATCL and EPT1 expression.Therefore,we implemented the lipidomic strategy and luciferase reporter assay to verify that ORI contributed to the homeostasis of lipids via the regulation of the ATGL gene associated with TG hydrolysis and the EPT1 gene related to PE synthesis in a LXRα-dependent manner,and the results showed the TG reduction and PE elevation.In detail,hepatic TG overload and lipotoxicity were reversed after ORI treatment by modulating the ATCL and EPT1 genes,respectively.Taken together,the data provide mechanistic insights to explain the bioactivity of ORI in attenuating TG accumulation and cytotoxicity and introduce exciting opportunities for developing novel natural activators of the LXRα-ATGL/EPT1 axis for pharmacologically treating hepatosteatosis and metabolic disorders.
摘要
OBJECTIVE To investigate the causal association between ticagrelor and risk of infection METHODS Two-sample Mendelian randomization was adopted. Genetic instrumental variables were selected based on the results of the largest genome-wide association analysis to in vivo exposure of ticagrelor and its major active metabolite AR-C124910XX. The causal associations of ticagrelor and its major active metabolite AR-C124910XX with drug indications (coronary artery disease, unstable angina pectoris, myocardial infarction, stroke and ischemic stroke)were analyzed by inverse variance weighted Mendelian randomization model as a positive control for genetic instrumental variables. The causal relationship between ticagrelor and bacterial infection, acute lower respiratory infection, bacterial pneumoniae, pneumoniae,acute upper respiratory infection and sepsis were furtheranalyzed by using this method, and the robustness of the results was assessed by using heterogeneity tests and horizontal 202002030415) pleiotropy tests. RESULTS The increase of area under the curve at steady state (AUCss) of the genetic surrogated ticagrelor significantly reduced the risk of coronary artery disease, myocardial infarction and unstable angina pectoris (P<0.001). AUCss genetic instrument variables of its main active metabolite AR-C124910XX failed to pass positive control. Further analysis showed that the increase of the genetic surrogated ticagrelor exposure suggestively reduced the risk of bacterial infection [OR(95%CI)=0.80(0.65,0.99),P=0.040] and sepsis [OR (95%CI)=0.84(0.73, 0.98), P=0.023]. The results of the heterogeneity tests showed that there was no heterogeneity in the causal association of the genetic surrogated ticagrelor AUCss with bacterial infection and sepsis (P>0.05). The results of horizontal pleiotropy tests showed that the causal association of genetic surrogated ticagrelor AUCss with bacterial infection and sepsis had no effects on horizontal pleiotropy (P>0.05). CONCLUSIONS Ticagrelor has a potential role in reducing the risk of sepsis and bacterial infections.
摘要
OBJECTIVE:To excavate the ADR signals of rivaroxaban and provide reference for its safe and rational use in clinic. METHODS :Based on FDA adverse event reporting system (FAERS),the ADRs of rivaroxaban reported from September 2008 to December 2020 in FDA ’s Open Data Program were mined using ratio of reports to odds (ROR)and proportional report ratio (PRR). The related ADRs were analyzed ,and the corresponding system organ classification (SOC)was mapped. At the same time,the basic information such as gender ,age and indications of the patients were statistically reported. RESULTS & CONCLUSIONS:Among 9 373 236 ADR reports extracted ,102 027 ADR reports with rivaroxaban as concomitant and suspected drug were obtained ;883 ADR signals were mined ,involving 27 systems. Among 102 027 reports,the proportion of female patients (41 294 cases,40.47%)was similar to that of male patients (41 071 cases,40.26%). The patients were mainly >50 to 75 years old(29 261 cases,28.68%)and >75 years old (21 470 cases,21.04%). The reporting year was mainly in 2018(18 446 cases, 18.08%);main reporting country was the United States (75 390 cases,73.89%);there were 35 046 cases(34.35%)of severe ADR reports ,mainly involving hospital or prolonged hospital stay. The SOC of rivaroxaban ADR singal mainly focused on diseases of the blood and lymphatic system ,vascular diseases ,various types of examination and nervous system diseases. Among top 20 preferred terms of ADRs with the highest frequency ,except for pulmonary embolism ,acute kidney injury and atrial fibrillation ,the rest were mainly bleeding related ADRs ,of which intracranial hemorrhage was the more seriou s ADR. Intracranial hemorrhage may occur when rivaroxaban is used for the prevention of atrial fibrillation and cerebrovascular accidents , and pulmonary embolism may occur when rivaroxaban is used for the prevention of pulmonary embolism ,(deep)venous thrombosis and thrombosis. Great importance should be paid on it.
摘要
OBJECTIVE:To excavate and evaluate ADR signals of SGLT 2 inhibitors as canagliflozin ,dapagliflozin and empagliflozin,and to provide reference for rational drug use in the clinic. METHODS :The proportional reporting ratio (PRR)and reporting odds ratio (ROR)were used to find the adverse drug reactions (ADR)signal of SGLT 2 inhibitors as canagliflozin , dapagliflozin and empagliflozin from the second quarter of 2013 to the third quarter of 2020 in the US FDA Adverse Event Reporting System (FAERS). The basic information (including gender ,age,reporting year ,reporting country ,severe ADR )and safety warning signals of corresponding patients in ADR report were analyzed. RESULTS :Among 6 029 375 ADR reports ,SGLT2 inhibitors of 43 807 ADR reports were concomitant and suspected drugs ;there were 19 301 ADR reports of canagliflozin ,10 960 ADR reports of dapagliflozin ,13 546 ADR reports of empagliflozin. Except for the ADR patients with unknown gender and missing age ,the gender distribution of the included reports was balanced ,mainly in the range of 50-75 years old. The reporting year was mainly in 2018,and the main reporting country was the United States ,with“hospitalization or prolonged hospitalization ” as the main serious ADR. A total of 573 ADR signals were obtained ,involving 26 systems,mainly focusing on metabolic and nutritional diseases ,endocrine disorders ,kidney and urinary system disease ,infection and invasion diseases ,etc. The results showed that there were 14 main ADR signals in the top 10 ADR of canagliflozin ,dapagliflozin and empagliflozin. The strongest ADR signals of dapagliflozin and empagliflozin were ketoacidosis (PRR=119.64/140.11,95%CI lower limit of ROR =148.28/ 178.78)and fungal infection (PRR=47.76/34.77,95% CI lower limit of ROR =50.69/36.28);except above signals in addition , toe amputation (PRR=489.79,95%CI lower limit of ROR =520.15)and osteomyelitis (PRR=61.42,95%CI lower limit of ROR=65.38)were strong in the ADR signals of canagliflozin. CONCLUSIONS :SGLT2 inhibitors have a higher security risk in metabolic and nutritional diseases ,endocrine disorders ,kidney and urinary system ,and infection and intrusion diseases. Dapagliflozin,canagliflozin and empag liflozin are prone to cause ADR such as ketoacidosis and fungal infection ,while canagliflozin is easy to cause ADRs such as toe amputation and osteomyelitis.
摘要
OBJECTIVE:To provide evidence-based reference for c linical drug selection and decision by rapidly evaluating the effectiveness,safety and economy of treprostinil in the treatment of pulmonary arterial hypertension (PAH). METHODS :Retrieved from Chinese and English database such as PubMed ,Embase,Web of Science ,the Cochrane Library ,Epistemonikos,HTA database(University of York ),CNKI and Wanfang databases ,included the health technology assessment (HTA)report,systematic/ Meta-analysis and pharmacoeconomic evaluation of treprostinil compared with placebo or other drugs in the treatment of PAH. The search time limit is from the construction of the database to May 1st,2020. HTA checklist ,AMSTA and CHEERS were applied to evaluate the quali ty of the literatures about HTA ,systematic review/Meta-analysis analysis a nd pharmacoecono mic evaluation and the inclusion studies was analyazed by descriptive summary. RESULTS:A total of 18 literatures were included ,involving 1 HTA report ,12 systematic review/Meta-analysis ,5 pharma- coeconomic studies. The analysis results of effectiven- ess mail: showed that compared with placebo ,treprostinil could signifi- cantly increase 6-MWD while decrease Borg dyspnea score of PAH p atients(P<0.05),but had no significant effect on mortality,the rate of clinical deterioration ,WHO functional grading ,the rate of hospitalization ,mPAP,PVR,cardiac index and mRAP(P>0.05). In addition ,compared with placebo combined with endothelin receptor antagonist and/or phosphodiesterase inhibitors,oral administration of treprostinil combined with endothelin receptor antagonist and/or phosphodiesterase inhibitors could extend 6-MWD significantly. Compared with riociguat ,treprostinil could significantly reduce Borg dyspnea score of patients. The analysis results of safety displayed that ,although the incidence of drug withdrawal due to can ’t tolerate ADR increased in patients receiving treprostinil ,there was no significant difference in the incidence of serious adverse events compared with placebo or other treatments,and it was better tolerated when administered by inhalation or intravenous injection. The analysis results of pharmacoeconomic studies showed that ICER of treprostinil was higher than the willingness payment threshold ,although the willingness payment threshold was different in different countries and different payers. CONCLUSIONS :Treprostinil treatment is effective for PAH. Patients may stop taking it due to can ’t tolerate ADR ,but the risk of serious adverse events are not increase. Although the price is high ,it is still an important alternative for PAH patients with clinical progress or poor prognosis.
摘要
OBJECTIVE@#To identify mitochondrial gene variants associated with statin-induced myalgia in Chinese patients with coronary artery disease (CHD).@*METHODS@#This study was conducted in a cohort of 403 patients with CHD receiving rosuvastatin therapy, among whom 341 patients had complete follow-up data concerning myalgia and 389 patients had documented measurements of plasma creatine kinase (CK) level. All these patients underwent genetic analysis using GSA chip for detecting mitochondria gene variants associated with myalgia. A logistic regression model was used to assess the association between 69 mitochondrial single-nucleotide polymorphisms (SNPs) and myopathy in 341 patients. The impact of these mutation sites on CK levels in 389 patients was evaluated by linear regression analysis.@*RESULTS@#G12630A variant was identified to correlate with an increased risk of myalgia in CHD patients (OR: 8.689, 95% @*CONCLUSIONS@#Mitochondrial G12630A variation is associated with statin-induced myalgia in patients with CHD, indicating the necessity of different treatment strategies for patients who carry this risk allele.
Subject(s)
Humans , China , Coronary Artery Disease/genetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Mitochondria , Myalgia , Polymorphism, Single Nucleotide摘要
OBJECTIVE@#To study the effect of CYP2D610 (c.100 C>T) on plasma trough concentrations of metoprolol and its metabolite α-hydroxy metoprolol, blood pressure and heart rate in patients with coronary artery disease.@*METHODS@#The patients with coronary artery disease taking metoprolol tablets (=128) and those taking metoprolol sustained-release tablets (=126) were genotyped for CYP2D610 using Taqman real-time quantitative PCR. The trough concentrations of metoprolol and α-hydroxy metoprolol were determined with UPLC-MS/MS, and the dose-normalized concentrations (C/D) were compared among the patients with different CYP2D610 genotypes in both groups. Resting blood pressure and heart rate were recorded in all the patients when the concentration of metoprolol reached the steady state and were compared among the patients with different genotypes.@*RESULTS@#In patients taking metoprolol sustained-release tablets, the plasma trough concentration of α-hydroxy metoprolol was significantly associated with the systolic blood pressure (=0.0204). The CYP2D610 poor metabolizers showed a significant association with the C/D of metoprolol and α-hydroxy metoprolol ( < 0.01) in patients receiving metoprolol in both formulations, and in both groups, the C/D of metoprolol was significantly higher in the patients with a TT genotype than in those with a CC or CT genotype ( < 0.01); compared with those with the CT genotype, the patients with the TT genotype had a significantly lower C/D of α-hydroxy metoprolol ( < 0.01). In patients taking metoprolol sustained-release tablets, those with the CT (=0.0281) and TT (=0.0196) genotypes had lower diastolic blood pressure than patients with the CC genotypes, but the systolic blood pressure or heart rate did not differ significantly among them.@*CONCLUSIONS@#CYP2D610T allele mutation can reduce the metabolism of metoprolol, increase the C/D of metoprolol and decrease the C/D of α-metoprolol and diastolic blood pressure in patients with coronary artery disease, but CYP2D610 variation does not significantly affect systolic blood pressure or heart rate in the patients when the concentration of metoprolol reaches a steady state.
Subject(s)
Humans , Adrenergic beta-Antagonists , Chromatography, Liquid , Coronary Artery Disease , Cytochrome P-450 CYP2D6 , Genotype , Metoprolol , Tandem Mass Spectrometry摘要
OBJECTIVE:To explore the genome-wide methylation differences between coronary heart disease (CHD) patients and healthy volunteers,and to investigate the relationsip of DNA methylation with CHD from epigenetics. METHODS:In case-control study,subjects were divided into CHD group(50 cases)and health control group(50 cases). DNA of 2 groups were sequenced with methylated DNA immunoprecipitation sequencing technology. The genome-wide methylation differences were analyzed and compared between 2 groups. RESULTS:The number of methylation peak in CHD group was higher than health group,with statistical signfi-cance(P<0.05). The methylation peak mainly distributed in 5'UTR,Intron functional elements. The number of reads in AQP1,SHB and other gene promoters in CHD group were lower than health group,and its methylation level decreased. The number of reads in GRK5 and serveal gene promoters on chrX in CHD group were higher than helath group,and its methylation level increased,with sta-tistical significance(P<0.01). CONCLUSIONS:The genome-wide methylation level of CHD patients are higher than those of healthy volunteers. The occurence of CHD is possibly associated with the change of methylation level of related gene promoters.
摘要
[ ABSTRACT] AIM:To investigate the characteristics of the intestinal microbial flora in the pregnant women with congenital heart disease fetus ( PW group) and normal pregnant women ( NW group) .METHODS: Stool samples were collected from 15 NW and 17 PW cases.The bacterial genomic DNA was extracted.The 16S rDNA was amplified by PCR, and the second generation of Illumina sequencing was conducted.RESULTS: We obtained 2 696 276 ( NW group) and 2 445 530 ( PW group) optimized sequences.The coverage was greater than 97%.We obtained 77 243 operational taxono-mic units ( OTUs) in NW group and 75 600 OTUs in PW group after a 97%similarity merge.In NW group, the Chao 1 in-dex and the Shannon index were greater than those in PW group.The diversity analysis of microbial population indicated that they were mainly composed of Firmicutes, Proteobacteria and Actinobacteria.In family, the Bifidobacteriaceae and Cori-obacteriaceae were significantly different through analysis of variance.CONCLUSION: The Bifidobacteriaceae and Cori-obacteriaceae may play an important role in the occurrence of congenital heart disease.
摘要
Objective To explore the correlation of the TIAM2 functional gene mutations with the bleeding events in patients with coronary heart disease who undergone PCI and postoperative taken anti-platelet drug clopi-dogrel. Methods One hundred and twenty Chinese Han patients who had undergone PCI and postoperative taken anti-platelet drug clopidogrel were orderly enrolled from Guangdong General Hospital. Followed for 6 months after PCI, PCR sequencing was applied to test TIAM2 promoter region genotyping assay. Results After follow-up six months , 113 cases were remained lost of 7 cases , , including 19 cases with bleeding and 94 cases without bleed-ing; Bleeding risk in patients with diabetes mellitus (OR=3.115) or taking statins (OR=11.539), may be high, but there was no significant difference (P > 0.05); TIAM2 promoter region had three variants (c.3168+3116C>T, c.3168+3261A>G,c.3168+3596A>C), including wild-type, heterozygous, and homozygous. The probability of pa-tients with bleeding were 36.84%, 52.63%and 10.53%, and there is a certain chain of state , but the genotype was not significantly correlated with bleeding events of clopidogrel antiplatelet therapy (P>0.05). Conclusion Clopi-dogrel antiplatelet therapy bleeding events were not significantly correlated with TIAM2 functional gene mutation.
摘要
Aim The current study was conducted to investigate the effect of GSTP1 codon 105 polymorphism, alone and in combination with GSTM1-deletion polymorphism, on erythrocyte GST activity in 196 Han Chinese. Methods GST activity was measured in healthy Chinese by a spectrophotometric method (n=196;101 males and 95 females; age range 21~81 years; median 43.5 years). GSTM1 polymorphisms were analyzed by a PCR-Multiplex procedure, whereas GSTP1 polymorphism was analyzed by PCR-RFLP. Results The frequency of GSTM1 null genotype was 56.1% and the frequency of I/I, I/V, and V/V genotypes was 60.7%, 35.2% and 4.1%, respectively, in Han Chinese. The mean erythrocyte GST enzyme activity for I/V genotype group(3.53?0.63 U?g -1Hb) was significantly lower than that for I/I genotypes (4.25?1.07 U?g -1Hb, P=0.000), while significantly higher than that for V/V genotypes (2.44?0.67 U?g -1Hb, P=0.004). In GSTM1(-) group, the GST activity of carriers of GSTM1(-)/GSTP1- I/I is significantly higher than that of GSTM1(-)/GSTP1- I/V or-V/V, however, in GSTM1(+) group, there is no difference between different subgroups. There was no significant difference in the mean GST activity among different age groups. Erythrocyte GST activities were significantly higher in females than in males, but not significantly. Conclusion The GST activity measured by CDNB-based assay is probably strongly correlated with the GSTP1 105Val genotype, although other GST enzymes would tend to dilute the GSTP1 genotype effect.